Casper N. S.
- Country
- Denmark
- Department
- Hæmatologisk Forskningsenhed
Research Overview
Data & Insights
Has run more than one trial at 0 of 5 partner sites.
Specializations
Hematologic Malignancies and Disorders
Investigator concentrates on diseases of the blood and marrow, including chronic myeloid leukemia and other myeloproliferative conditions.
- Targeted inhibition in chronic myeloid leukemia
- Combination strategies for acute myeloid leukemia
- Optimizing dosing in haematological diseases across disease domains
- Biomarker‑driven therapy for myeloproliferative neoplasms
Therapeutic efforts aim to improve survival and disease‑free outcomes in patients with blood‑forming organ disorders.
Breast Cancer Therapeutics
Research emphasizes advanced and early‑stage breast malignancies, with particular attention to HER2‑positive and triple‑negative subtypes.
- Antibody‑drug conjugates for high‑risk HER2‑positive breast cancer
- Capecitabine augmentation in neoadjuvant triple‑negative breast cancer
- Endocrine resistance mitigation in HR‑positive/HER2‑negative disease
- Adjuvant strategies for early triple‑negative breast cancer
Therapeutic focus is on extending invasive‑disease‑free survival and reducing recurrence across breast cancer phenotypes.
Cardiovascular and Heart Failure Research
Investigator engages in trials addressing cardiac dysfunction, including heart failure with reduced ejection fraction and metabolic modulation of cardiac outcomes.
- Myosin inhibition with mavacamten in obstructive cardiomyopathy
- SGLT2 inhibition combined with vicadrostat for advanced heart failure
- Metformin and hydralazine‑ISDN regimens in chronic heart failure
- Goal‑directed fluid removal using intravenous furosemide
Therapeutic aim is to lower cardiovascular mortality, hospitalisation, and symptom burden in heart disease patients.
Lung Cancer and Thoracic Oncology
Work includes both non‑small cell and small‑cell lung malignancies, with a focus on molecularly defined subsets such as KRAS G12C‑mutated disease.
- KRAS‑targeted therapy combined with pembrolizumab
- Single‑agent and combination regimens for relapsed small‑cell lung cancer
- Immunotherapy augmentation in non‑squamous non‑small cell lung cancer
- Response monitoring using advanced imaging in metastatic lung disease
Therapeutic objectives centre on improving overall survival and progression‑free intervals for thoracic cancer patients.
Infectious Diseases and Critical Care
Investigator contributes to management of severe infections and ICU conditions, including complicated urinary tract infections and sepsis‑related organ failure.
- Antibiotic optimization for cUTI in hospitalized adults
- Prophylactic strategies for bloodstream infection in hemodialysis patients
- Fluid‑overload management with diuretics in intensive care
- Airway management agents for video‑laryngoscopy‑guided intubation
Therapeutic focus seeks to reduce mortality, shorten hospital stay, and limit antibiotic resistance in critically ill populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.